Video

Developing new measurements for better MS outcomes


 

EXPERT ANALYSIS FROM CMSC 2019

Researchers are working on new tools to objectively measure several domains affected by multiple sclerosis (MS) in hope of improving patient care, according to Jared Srinivasan.

Mr. Srinivasan, a research coordinator at South Shore Neurologic Associates in Patchogue, N.Y., sat down at the annual meeting of the Consortium of Multiple Sclerosis Centers for a video interview summarizing his work on new measurement tools for assessing disease status in MS patients with Mark Gudesblatt, MD, and other colleagues at South Shore Neurologic Associates.

“We are trying to find better ways of measuring disease status, rather than the EDSS [Expanded Disability Status Scale] ... It is not as sensitive as some other measures can be,” Mr. Srinivasan said. “We are trying to shed light on some new tools regarding objectively measuring cognition, manual dexterity, gait, and ocular coherence tomography.”

The overall goal, he said, “is to use a combination of these granular outcome measures to create a bigger picture of a patient’s disease so we can better treat them.”

One of the tools is called Neurotrax, which measures cognition in multiple dimensions (e.g., attention, information processing, motor skills, verbal functioning). With this and other new tools for manual dexterity and its cognitive aspects, as well as other dimensions of MS, the researchers are trying capture a fuller picture of MS in individual patients.

“The end goal of this is that if we can show that MS is such a complex disease that the current tools we are using do not quite capture the full nuances and granularity in it, then we can move toward using better measures that will capture that, which will move patient care forward.”

Mr. Srinivasan had nothing to disclose.

Recommended Reading

Low baseline heart rate may not increase cardiac risk when starting fingolimod
MDedge Neurology
Mental illness in MS: ‘Follow the why’
MDedge Neurology
Patients with MS who consider using marijuana are more likely to engage in risky behaviors
MDedge Neurology
High-efficacy DMTs may reduce depressive symptoms in MS
MDedge Neurology
Which interventions can treat cognitive fatigue?
MDedge Neurology
Evidence lacking in treatments for pain in MS
MDedge Neurology
MS patients pay big price for breaks from DMT
MDedge Neurology
Even if successful, IVF may boost relapses in MS
MDedge Neurology
Switching from interferon beta-1a to alemtuzumab improves MS outcomes
MDedge Neurology
Mindfulness meditation may boost cognition in MS
MDedge Neurology